Recent Updates
Recently added Catalysts

Durvalumab

Phase 2

Lung Cancer Stage II | Small molecule | Oncology |Atrium Therapeutics, Inc.|Last Updated: Feb 5, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment61

FDA Designations

No designations recorded

Clinical trial landscape

Durvalumab · 1 trial · 3 indications

Phase 2 1
NCT03141359Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLCLung Cancer Stage II
ACTIVE NOT_RECRUITING61 Analytics
PHASE2ACTIVE NOT_RECRUITING
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
Lung Cancer Stage II
NCT0314135961
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants Progression Free and Surviving at 12 Months
From date of treatment start to date of progression or death, or censored at 12 months, whichever occurred first.

12-month progression free survival was determined for each subject as a binary variable indicating whether or not the subject was progression free and surviving at 12 months after study enrollment. Failure occurred if the subject progressed or died from any cause within 12 months of study enrollment. Disease progression was determined according to RECIST v1.1.

Secondary Endpoints

Progression Free Survival (PFS)
From date of treatment start to date of progression or death, or censored as described; assessed for approximately 5 years
Overall Survival (OS)
From date of treatment start to date of death, or censored as described; assessed for approximately 5 years
Radiologic Clinical Complete Response
Approximately 3 months after last treatment of concurrent mediastinal chemoradiation (on average, SBRT plus chemoradiation treatment lasted 2 months from baseline)
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single ArmEXPERIMENTALSBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy

Interventions

NameTypeDescription
SBRTRADIATIONPrimary tumor SBRT
CarboplatinDRUGconcurrent chemotherapy
PaclitaxelDRUGconcurrent chemotherapy
cis PlatinumDRUGconcurrent chemotherapy
EtoposideDRUGconcurrent chemotherapy
IMRTRADIATIONmediastinal radiation
DurvalumabDRUGadjuvant immunotherapy
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria Subjects must meet all the following criteria: * Histologic or cytologic documentation of NSCLC (all histologies allowed) * Stage II or III disease (AJCC 7th Edition) based on imaging as required during screening: Stage II disease includes only subjects with medically inoperable...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWMay 24, 2026NCT03141359studyFirstPostDate: changed

Frequently asked questions about Durvalumab

What is Durvalumab used for in Lung Cancer Stage II?

Durvalumab is being studied for use in Lung Cancer Stage II, as well as Lung Cancer Stage III and Non Small Cell Lung Cancer. It is an investigational oncology therapy currently in Phase 2 clinical development, evaluated in a trial that combines high dose radiation followed by chemotherapy and radiation.

What does Durvalumab target?

Durvalumab is a small molecule therapy developed by Atrium Therapeutics, Inc. for oncology indications. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its potential role in treating lung cancers, including Stage II and Stage III disease.

Who makes Durvalumab?

Durvalumab is being developed by Atrium Therapeutics, Inc., a biopharmaceutical company. The company's stock ticker is RNA. Atrium Therapeutics is conducting clinical research on Durvalumab for the treatment of lung cancer, with the drug currently in Phase 2 development.

What phase is Durvalumab in?

Durvalumab is currently in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants, and is designed to evaluate the therapy in patients with lung cancer.

What clinical trials is Durvalumab in?

Durvalumab is being evaluated in one clinical trial, identified as NCT03141359. This Phase 2 study, titled 'Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC,' is active but not recruiting. The trial enrolls 61 participants in the United States and includes patients with Lung Cancer Stage II, Stage III, and Non Small Cell Lung Cancer.

Is Durvalumab the same as any other drug?

Durvalumab is the drug name used in the clinical trial records for this investigational therapy. No alternative names have been listed in the available information. The drug is being developed by Atrium Therapeutics, Inc. and is currently in Phase 2 testing for lung cancer indications.